Miguel Loyola

Dr. Miguel Loyola

investigación, Hospital Juárez de México, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Luis Uriel Gonzalez-AvilaLuis Uriel Gonzalez-Avila
Luis Uriel Gonzalez-Avila
Miguel LoyolaMiguel Loyola
Miguel Loyola
CCCecilia Hernández Cortez
Cecilia Hernández Cortez
Juan Manuel Bello-LópezJuan Manuel Bello-López
Juan Manuel Bello-López
GRACIELA CASTRO-ESCARPULLIGRACIELA CASTRO-ESCARPULLI
GRACIELA CASTRO-ESCARPULLI
The increase in the use of antimicrobials such as colistin for the treatment of infectious diseases has led to the appearance of Aeromonas strains resistant to this drug. However, resistance to colistin not only occurs in the clinical area but has also been determined in Aeromonas isolates from the environment or animals, which has been determined by the detection of mcr genes that confer a resistance mechanism to colistin. The variants mcr-1, mcr-3, and mcr-5 have been detected in the genus Aeromonas in animal, environmental, and human fluids samples. In this article, an overview of the resistance to colistin in Aeromonas is shown, as well as the generalities of this molecule and the recommended methods to determine colistin resistance to be used in some of the genus Aeromonas.

22 May 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
Miguel LoyolaMiguel Loyola
Miguel Loyola
Luis Uriel Gonzalez-AvilaLuis Uriel Gonzalez-Avila
Luis Uriel Gonzalez-Avila
Arturo Martínez-TrejoArturo Martínez-Trejo
Arturo Martínez-Trejo
Andres Saldaña-PadillaAndres Saldaña-Padilla
Andres Saldaña-Padilla
CCCecilia Hernández Cortez
Cecilia Hernández Cortez
GRACIELA CASTRO-ESCARPULLIGRACIELA CASTRO-ESCARPULLI
GRACIELA CASTRO-ESCARPULLI
The ESKAPE group constitute a threat to public health, since these microorganisms are associated with severe infections in hospitals and have a direct relationship with high mortality rates. The presence of these bacteria in hospitals had a direct impact on the incidence of healthcare-associated coinfections in the SARS-CoV-2 pandemic. In recent years, these pathogens have shown resistance to multiple antibiotic families. The presence of high-risk clones within this group of bacteria contributes to the spread of resistance mechanisms worldwide. In the pandemic, these pathogens were implicated in coinfections in severely ill COVID-19 patients. The aim of this review is to describe the main microorganisms of the ESKAPE group involved in coinfections in COVID-19 patients, addressing mainly antimicrobial resistance mechanisms, epidemiology, and high-risk clones.

Verified
Journal Article
Open access
PDF file
Arturo Martínez-TrejoArturo Martínez-Trejo
Arturo Martínez-Trejo
JRJuan Manuel Ruiz-Ruiz
Juan Manuel Ruiz-Ruiz
Luis Uriel Gonzalez-AvilaLuis Uriel Gonzalez-Avila
Luis Uriel Gonzalez-Avila
Andres Saldaña-PadillaAndres Saldaña-Padilla
Andres Saldaña-Padilla
CCCecilia Hernández Cortez
Cecilia Hernández Cortez
GRACIELA CASTRO-ESCARPULLIGRACIELA CASTRO-ESCARPULLI
GRACIELA CASTRO-ESCARPULLI
Acinetobacter baumannii is a Gram-negative bacillus that causes multiple infections that can become severe, mainly in hospitalized patients. Its high ability to persist on abiotic surfaces and to resist stressors, together with its high genomic plasticity, make it a remarkable pathogen. Currently, the isolation of strains with high antimicrobial resistance profiles has gained relevance, which complicates patient treatment and prognosis. This resistance capacity is generated by various mechanisms, including the modification of the target site where antimicrobial action is directed. This mechanism is mainly generated by genetic mutations and contributes to resistance against a wide variety of antimicrobials, such as β-lactams, macrolides, fluoroquinolones, aminoglycosides, among others, including polymyxin resistance, which includes colistin, a rescue antimicrobial used in the treatment of multidrug-resistant strains of A. baumannii and other Gram-negative bacteria. Therefore, the aim of this review is to provide a detailed and up-to-date description of antimicrobial resistance mediated by the target site modification in A. baumannii, as well as to detail the therapeutic options available to fight infections caused by this bacterium.

22 August 2022 in American Journal of Infection Control
Verified
Journal Article
Closed access
Miguel LoyolaMiguel Loyola
Miguel Loyola
EDEmilio Mariano Durán-Manuel
Emilio Mariano Durán-Manuel
CCClemente Cruz-Cruz
Clemente Cruz-Cruz
LMLaura Margarita Márquez-Valdelamar
Laura Margarita Márquez-Valdelamar
JBJuan Carlos Bravata-Alcántara
Juan Carlos Bravata-Alcántara
Juan Manuel Bello-LópezJuan Manuel Bello-López
Juan Manuel Bello-López

4 January 2024 in Pathogens
Verified
Journal Article
Open access
PDF file
MCMónica Alethia Cureño-Diaz
Mónica Alethia Cureño-Diaz
EPEstibeyesbo Said Sigmund Reivaj Plascencia-Nieto
Estibeyesbo Said Sigmund Reivaj Plascencia-Nieto
Miguel LoyolaMiguel Loyola
Miguel Loyola
Clemente Cruz-CruzClemente Cruz-Cruz
Clemente Cruz-Cruz
ANAndres Emmanuel Nolasco
Andres Emmanuel Nolasco
Juan Manuel Bello-LópezJuan Manuel Bello-López
Juan Manuel Bello-López
The interruption of bacteriological surveillance due to the COVID-19 pandemic brought serious consequences, such as the collapse of health systems and the possible increase in antimicrobial resistance. Therefore, it is necessary to know the rate of resistance and its associated mechanisms in bacteria causing hospital infections during the pandemic. The aim of this work was to show the phenotypic and molecular characteristics of antimicrobial resistance in ESKAPE bacteria in a Mexican tertiary care hospital in the second and third years of the pandemic. For this purpose, during 2021 and 2022, two hundred unduplicated strains of the ESKAPE group (Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii) were collected from various clinical sources and categorized by resistance according to the CLSI. An analysis of variance (ANOVA) complemented by the Tukey test was performed to search for changes in antimicrobial susceptibility profiles during the study period. Finally, the mechanisms of resistance involved in carbapenem resistance were analyzed, and the search for efflux pumps and high-risk sequence types in A. baumannii was performed by multilocus analysis (MLST). The results showed no changes in K. pneumoniae resistance during the period analyzed. Decreases in quinolone resistance were identified in E. coli (p = 0.039) and P. aeruginosa (p = 0.03). Interestingly, A. baumannii showed increases in resistance to penicillins (p = 0.004), aminoglycosides (p < 0.001, p = 0.027), carbapenems (p = 0.027), and folate inhibitors (p = 0.001). Several genes involved in carbapenem resistance were identified (blaNDM, blaVIM, blaOXA, blaKPC, blaOXA-40, and blaOXA-48) with a predominance of blaOXA-40 and the adeABCRS efflux pump in A. baumannii. Finally, MLST analysis revealed the presence of globally distributed sequence types (ST369 and ST758) related to hospital outbreaks in other parts of the world. The results presented demonstrate that the ESKAPE group has played an important role during the COVID-19 pandemic as nosocomial antibiotic-resistant pathogens and in particular A. baumannii MDR as a potential reservoir of resistance genes. The implications of the increases in antimicrobial resistance in pathogens of the ESKAPE group and mainly in A. baumannii during the COVID-19 pandemic are analyzed and discussed.

20 September 2021 in American Journal of Infection Control
Verified
Journal Article
Closed access
MCMonica Alethia Cureño-Díaz
Monica Alethia Cureño-Díaz
EDEmilio Mariano Durán-Manuel
Emilio Mariano Durán-Manuel
CCClemente Cruz-Cruz
Clemente Cruz-Cruz
GIGabriela Ibáñez-Cervantes
Gabriela Ibáñez-Cervantes
MRMaría Isabel Rojo-Gutiérrez
María Isabel Rojo-Gutiérrez
Juan Manuel Bello-LópezJuan Manuel Bello-López
Juan Manuel Bello-López